Par inks $410M deal for niche generics maker Anchen

Par Pharmaceutical ($PRX) is adding to its stable of generic meds with a $410 million buyout. The deal with Anchen Pharmaceuticals will bring 5 marketed products and another 27 awaiting approval from FDA. Privately held, Anchen focuses on extended release generics and niche knockoff drugs, the company said in a statement.

Based in Irvine, CA, Anchen expects to launch 8-10 generics over the next two years, Par said, and 5 of its pending FDA apps cover drugs that are believed to have first-to-file status--and the coveted 180-day exclusivity that goes along with it.

But Anchen's attractions aren't just its products. The company's manufacturing capacity and "state-of-the-art equipment," not to mention R&D capabilities, are key to the deal, too. All this, "combined with Par's existing capabilities and pipeline, more than doubles our product opportunities," CEO Patrick LePore said in a statement.

The deal will be financed with cash on hand, plus a $350 million loan. Par expects Anchen to add to earnings immediately. It's the company's second buyout this year, Reuters notes, after a $37.6 million deal to buy India's Edict Pharmaceuticals.

- see the release from Par
- get more from Reuters

Suggested Articles

Bluebird Bio has overcome a manufacturing hiccup that looked like it would delay its gene therapy launch in Europe until next year.

Lilly's top U.S. executive is on his way out. Enrique Conterno, who also heads up Lilly's global diabetes business, will step down at year's end.

GlaxoSmithKline, Pfizer, Sanofi and Boehringer Ingelheim are facing lawsuit claims that they failed to test for possible carcinogens in Zantac.